Antibiotic market to reach US$ 74.07 billion by 2033; FDA approves GSK’s Blujepa for uncomplicated UTIs

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

Nocutil

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

59 API Suppliers, 20 USDMF, 14 CEP/COS, 2 JDMF, 3 EU WC, 10 KDMF, 30 NDC API, 18 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

31 Drugs in Development

31 Drugs in Development

FINISHED DOSAGE FORMULATIONS

329 FDF Dossiers, 53 FDA Orange Book, 228 Europe, 12 Canada, 12 Australia, 8 South Africa, 16 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SOLUTION;NASAL - 0.01%, SPRAY, METERED;NASAL - 0.01MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - 0.004MG/ML, TABLET;ORAL - 0.1MG, TABLET;ORAL - 0.2MG, SPRAY, METERED;NASAL - 0.00083MG/SPRAY, SPRAY, METERED;NASAL - 0.00166MG/SPRAY, SPRAY, METERED;NASAL - 0.15MG/SPRAY, SPRAY, METERED;NASAL - 0.01MG/SPRAY, TABLET;SUBLINGUAL - 0.0277MG, TABLET;SUBLINGUAL - 0.0553MG

RELATED EXCIPIENT COMPANIES

3 SPI Pharma, 1 DKSH, 8 Boai NKY Pharmaceuticals Ltd, 2 Gangwal Healthcare, 3 Nanjing Well Pharmaceutical, 3 Kirsch Pharma, 7 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 15 BASF, 1 CD Formulation, 2 DFE Pharma, 1 Finar, 7 Gangwal Chemicals, 2 Ingredion Pharma Solutions, 12 Kerry, 10 Microlex e.U, 1 Nitika Pharmaceutical Specialities, 2 Novo Excipients, 2 Pharmatrans-Sanaq, 4 Pluviaendo, 1 Prachin Chemical, 7 Roquette, 5 Seppic, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 3 Sigachi Industries, 1 Silverline Chemicals, 1 Symrise, 2 Ulanqab Kema New Material, 1 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

39 Fillers, Diluents & Binders, 19 Disintegrants & Superdisintegrants, 19 Direct Compression, 17 Solubilizers, 17 Granulation, 13 Parenteral, 13 Lubricants & Glidants, 10 Thickeners and Stabilizers, 9 Chewable & Orodispersible Aids, 7 Co-Processed Excipients, 7 Controlled & Modified Release, 7 Emulsifying Agents, 5 Taste Masking, 5 Topical, 5 Surfactant & Foaming Agents, 3 Film Formers & Plasticizers, 3 Coating Systems & Additives, 2 API Stability Enhancers

DIGITAL CONTENT

31 News #PharmaBuzz

31 News #PharmaBuzz

GLOBAL SALES INFORMATION

18 US Medicaid Prescriptions, 106 Regulatory FDF Prices

MARKET PLACE

9 APIs, 8 FDF Dossiers

PATENTS & EXCLUSIVITIES

12 US Patents, 14 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 3 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
29/11/2025	Anygen	South Korea	HLB Pep Co., Ltd.	20180905-209-J-198	Desmopressin acetate	2018-09-05	HLB Pep Co., Ltd.	South Korea	Test Production Building 2 (3-story building) within the Jeollanam-do Nanobio Center, 123 Nanosandan-ro, Nammyeon, Jangseong-gun, Jeollanam-do
29/11/2025	Hybio Pharmaceutical	China	SG Biochem Co., Ltd.	20181018-209-J-84	Desmopressin acetate	2018-10-18	Hybio Pharmaceutical Co., Ltd.	China	No.37, keji C.2nd Street. Shenzhen Hi-tech Industrial Park. Guangdong PRChina

Nocutil

Nocutil

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

59 API Suppliers

20 USDMF

14 CEP/COS

2 JDMF

3 EU WC

10 KDMF

30 NDC API

18 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

31 Drugs in Development

FINISHED DOSAGE FORMULATIONS

329 FDF Dossiers

53 FDA Orange Book

228 Europe

12 Canada

12 Australia

8 South Africa

16 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SOLUTION;NASAL - 0.01%

SPRAY, METERED;NASAL - 0.01MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - 0.004MG/ML

TABLET;ORAL - 0.1MG

TABLET;ORAL - 0.2MG

SPRAY, METERED;NASAL - 0.00083MG/SPRAY

SPRAY, METERED;NASAL - 0.00166MG/SPRAY

SPRAY, METERED;NASAL - 0.15MG/SPRAY

SPRAY, METERED;NASAL - 0.01MG/SPRAY

TABLET;SUBLINGUAL - 0.0277MG

TABLET;SUBLINGUAL - 0.0553MG

RELATED EXCIPIENT COMPANIES

3 SPI Pharma

1 DKSH

8 Boai NKY Pharmaceuticals Ltd

2 Gangwal Healthcare

3 Nanjing Well Pharmaceutical

3 Kirsch Pharma

7 Actylis

1 Aeon Procare

1 Alcedo Pharmachem

4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

2 Ashland

15 BASF

1 CD Formulation

2 DFE Pharma

1 Finar

7 Gangwal Chemicals

2 Ingredion Pharma Solutions

12 Kerry

10 Microlex e.U

1 Nitika Pharmaceutical Specialities

2 Novo Excipients

2 Pharmatrans-Sanaq

4 Pluviaendo

1 Prachin Chemical

7 Roquette

5 Seppic

3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

3 Sigachi Industries

1 Silverline Chemicals

1 Symrise

2 Ulanqab Kema New Material

1 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

39 Fillers, Diluents & Binders

19 Disintegrants & Superdisintegrants

19 Direct Compression

17 Solubilizers

17 Granulation

13 Parenteral

13 Lubricants & Glidants

SPRAY, METERED;NASAL - 0.01MG/SPRAY Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons